Home/Filings/4/A/0001493152-21-032696
4/A//SEC Filing

LaFrence Andrew D.C. 4/A

Accession 0001493152-21-032696

CIK 0001349929other

Filed

Dec 28, 7:00 PM ET

Accepted

Dec 29, 4:30 PM ET

Size

6.4 KB

Accession

0001493152-21-032696

Insider Transaction Report

Form 4/AAmended
Period: 2021-11-23
LaFrence Andrew D.C.
Chief Financial Officer
Transactions
  • Purchase

    Common Stock, $0.0001 par value

    2021-11-23$2.00/sh+5,000$9,99834,292 total
Holdings
  • Common Stock, $0.0001 par value

    (indirect: By Trust)
    29,825
Footnotes (2)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.9995 to $2.00 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
  • [F2]Includes 3,000 shares previously held directly by the Reporting Person which were transferred to this joint trust account.

Documents

1 file

Issuer

Vyant Bio, Inc.

CIK 0001349929

Entity typeother

Related Parties

1
  • filerCIK 0001850633

Filing Metadata

Form type
4/A
Filed
Dec 28, 7:00 PM ET
Accepted
Dec 29, 4:30 PM ET
Size
6.4 KB